Trial Profile
Randomized, Multi-center, Open-label Phase III Study of the Efficacy and Safety of Flumatinib vs Imatinib as First Line Treatment in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Flumbatinib (Primary) ; Imatinib
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms FESTnd
- Sponsors Jiangsu Hansoh Pharmaceutical
- 14 Sep 2020 Primary endpoint (SIX-month major molecular response rate) has been met.
- 14 Sep 2020 Results published in the Clinical Cancer Research
- 24 Feb 2018 Status changed from recruiting to completed.